Novartis says nine tumor reports have occurred in children treated with its SMA gene therapy onasemnogene abeparvovec (Zolgensma), prompting renewed scrutiny of risks associated with AAV-based therapies. MedPage Today reports the company acknowledgement and notes that two cases involved evidence related to the viral delivery tool, according to the summary provided.
BioPharma Dive similarly focuses on the possibility that a viral delivery component may have integrated into patient DNA in some instances, describing nine recipients in total and emphasizing how the details could affect broader questions for the gene therapy field. STAT News also highlights tumor risk concerns tied to AAV gene therapies like Zolgensma, repeatedly returning to Novartis’s disclosures of previously unknown tumor cases.
Some STAT items add that Novartis cited additional, previously unreported cases beyond earlier public information, describing seven or similar numbers in particular headlines. Overall, outlets agree on the core facts of Novartis acknowledging multiple tumor cases after Zolgensma treatment, while they differ in how much they stress DNA-integration evidence and whether they foreground totals versus newly reported counts.
